Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NRIX Nurix Therapeutics

交易中 11-06 11:19:12 EST

15.21

+0.37

+2.49%

最高15.45	最低14.79	成交量91.45万
今开15.10	昨收14.84	日振幅4.44%
总市值16.58亿	流通市值12.10亿	总股本1.09亿
成交额1,388万	换手率1.15%	流通股本7,958万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":15.21,"timestamp":1793981952267,"preClose":14.84,"halted":0,"volume":914451,"delay":0,"changeRate":0.02493261455525613,"floatShares":79580000,"shares":109000000,"eps":2.43,"marketStatus":"交易中","change":0.37,"latestTime":"11-06 11:19:12 EST","open":15.1,"high":15.45,"low":14.791,"amount":13879029.757695,"amplitude":0.044407,"askPrice":15.22,"askSize":130,"bidPrice":15.19,"bidSize":68,"shortable":3,"etf":0,"ttmEps":2.43,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1793998800000},"marketStatusCode":2,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":14.84,"preHourTrading":{"tag":"盘前","latestPrice":15.01,"preClose":14.84,"latestTime":"09:29 EST","volume":2472,"amount":37129.756416,"timestamp":1793975398746,"change":0.17,"changeRate":0.011456,"amplitude":0.027628},"postHourTrading":{"tag":"盘后","latestPrice":14.92,"preClose":14.84,"latestTime":"19:49 EST","volume":890455,"amount":13215473.2192,"timestamp":1793926193036,"change":0.08,"changeRate":0.005391,"amplitude":0.025606},"volumeRatio":0.454115,"impliedVol":0.7982,"impliedVolPercentile":0.7012},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"2680054417","title":"赛诺菲(SNY.US)叫停STAT6项目，Nurix(NRIX.US)盘前跌超30%！里程碑款与分成一并落空","url":"https://stock-news.laohu8.com/highlight/detail?id=2680054417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680054417?lang=zh_cn&edition=full","pubTime":"2026-11-04 21:28","pubTimestamp":1793798880,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Nurix Therapeutics在宣布其合作伙伴赛诺菲决定停止一项实验性炎症疾病疗法的研究后，于周三盘前延续了此前的盘后跌势。截至发稿，Nurix 跌32.96%，报17.31美元。此前数月，这家法国制药巨头刚于今年8月启动针对2型炎症性疾病的STAT6降解剂SAR448272的一期临床开发，并由此向Nurix支付了1000万美元里程碑款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["NRIX","BK4588","BK4585","BK4139","IE00BFXG1179.USD","SNY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119072515","title":"Nurix宣布启动Stat6降解剂1期临床试验，获1000万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1119072515","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119072515?lang=zh_cn&edition=full","pubTime":"2026-08-04 19:01","pubTimestamp":1785841286,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，因启动一项针对Stat6降解剂的1期临床试验，该公司已收到1000万美元的里程碑付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181416540","title":"Nurix Therapeutics 宣布复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤临床试验Daybreak CLL-306首批患者入组，Bexobrutideg进入关键性3期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=1181416540","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1181416540?lang=zh_cn&edition=full","pubTime":"2026-08-04 13:01","pubTimestamp":1785819672,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics 宣布其关键性3期临床试验 Daybreak CLL-306 已完成首批患者入组。该试验旨在评估 bexobrutideg 针对复发/难治性慢性淋巴细胞白血病与小淋巴细胞淋巴瘤的疗效。这一里程碑事件，标志着这家生物科技公司向监管注册迈出了坚实的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173713352","title":"Nurix Therapeutics 与罗氏携手推进Bexobrutinib在CLL、B细胞恶性肿瘤、MS及CSU领域的发展","url":"https://stock-news.laohu8.com/highlight/detail?id=1173713352","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173713352?lang=zh_cn&edition=full","pubTime":"2026-07-22 04:03","pubTimestamp":1784664195,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics 与罗氏达成合作，将共同推进药物Bexobrutinib在慢性淋巴细胞白血病（CLL）、B细胞恶性肿瘤、多发性硬化症（MS）以及慢性自发性荨麻疹（CSU）等多个适应症中的研发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144131445","title":"Nurix与罗氏研发成本分摊比例敲定：四六开，美国市场损益均分","url":"https://stock-news.laohu8.com/highlight/detail?id=1144131445","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144131445?lang=zh_cn&edition=full","pubTime":"2026-07-22 04:02","pubTimestamp":1784664136,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics与合作伙伴罗氏就一项关键研发协议达成成本分摊细则。根据协议，双方将共同承担候选药物的开发费用，其中Nurix Therapeutics负担40%，罗氏承担60%。此外，在美国市场产生的所有利润与亏损，将由两家公司平均分配。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136550694","title":"Nurix Therapeutics宣布与罗氏全球合作获得HSR批准，将共同开发并商业化潜在同类最佳BTK降解剂Bexobrutideg，覆盖恶性血液病、免疫学及神经学领域","url":"https://stock-news.laohu8.com/highlight/detail?id=1136550694","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136550694?lang=zh_cn&edition=full","pubTime":"2026-07-22 04:02","pubTimestamp":1784664135,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，其与罗氏（Roche）达成的全球合作协议已获得美国《哈特-fullName-斯科特-罗迪诺反垄断改进法》（HSR）的批准。该合作旨在共同开发并商业化潜在同类最佳的布鲁顿酪氨酸激酶（BTK）降解剂Bexobrutideg，其应用范围将广泛覆盖恶性血液病、免疫学及神经学等多个治疗领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120668408","title":"Nurix Therapeutics 1a期数据：重度预处理复发/难治性CLL/SLL患者中位无进展生存期达22.1个月，总缓解率83%","url":"https://stock-news.laohu8.com/highlight/detail?id=1120668408","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120668408?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:04","pubTimestamp":1781175859,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics公布的最新1a期临床试验数据显示，其研究性疗法在重度预处理的复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者群体中，展现出令人鼓舞的疗效。该患者群体既往接受过多线治疗，临床需求高度未满足。关键疗效指标显示，患者的中位无进展生存期达到了22.1个月，总缓解率高达83%。这些积极数据为后续临床开发提供了有力支持，并凸显了该疗法在治疗这一难治性血液恶性肿瘤方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115642144","title":"Nurix Therapeutics将公布Btk降解剂Bexobrutideg最新1a/b期数据，凸显在复发/难治性CLL/SLL中的持久应答及早期治疗线中的积极活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1115642144","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115642144?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:01","pubTimestamp":1781175683,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics即将公布其Btk降解剂Bexobrutideg的更新版1a/b期临床试验结果。最新数据显示，该药物在治疗复发或难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中，能够诱导出持久的治疗应答。同时，在更早治疗线中的应用也展现出令人鼓舞的活性，为拓展其临床适用范围带来了希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163288696","title":"Nurix Therapeutics公布二线BTKi经治、BCL2i初治CLL患者92.9%客观缓解率","url":"https://stock-news.laohu8.com/highlight/detail?id=1163288696","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163288696?lang=zh_cn&edition=full","pubTime":"2026-06-11 19:01","pubTimestamp":1781175679,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics公布了其药物在二线治疗慢性淋巴细胞白血病患者中的最新数据。这些患者先前接受过布鲁顿酪氨酸激酶抑制剂治疗，但未接触过BCL2抑制剂。结果显示，客观缓解率达到了92.9%，展现了显著的临床活性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641100114","title":"罗氏(RHHBY)收购Nurix(NRIX)旗下靶向降解剂Bexobrutideg的商业开发权益 涉资最高可达30亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641100114","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641100114?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:11","pubTimestamp":1780909874,"startTime":"0","endTime":"0","summary":"当地时间周一，临床阶段生物制药公司Nurix Therapeutics正式宣布，已与全球跨国制药巨头罗氏达成一项总额最高可达30亿美元的全球战略合作协议。两家公司将共同开发并商业化口服BTK降解剂Bexobrutideg。据介绍，本次让罗氏不惜砸下重金的核心资产Bexobrutideg，是一款具备“同类最佳”潜力的口服、可穿透血脑屏障的小分子BTK靶向蛋白降解剂。截至本文发稿，Nurix美股盘前大涨56.15%，最新报22.90美元。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301245","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","NRIX","03165","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160719437","title":"罗氏将向Nurix支付高达23亿美元的癌症药物交易款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1160719437","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160719437?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:42","pubTimestamp":1780908153,"startTime":"0","endTime":"0","summary":"6月5日，Nurix Therapeutics盘前一度飙涨近70%！罗氏发表声明称，已与生物制药公司Nurix Therapeutics达成独家许可与合作协议。罗氏将支付最高23亿美元，以获得Nurix一种实验性血液癌症药物的权益。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108856417","title":"罗氏与Nurix Therapeutics就BTK降解剂Bexobrutideg达成全球合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1108856417","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108856417?lang=zh_cn&edition=full","pubTime":"2026-06-08 13:20","pubTimestamp":1780896038,"startTime":"0","endTime":"0","summary":"罗氏控股公司宣布，将与Nurix Therapeutics建立全球性合作，共同开发和商业化一款潜在同类最佳的BTK降解剂Bexobrutideg，其应用范围将覆盖恶性血液肿瘤、免疫学及神经学领域。\n根据协议条款，Nurix公司将获得高达23亿美元的总交易价值，其中包括7亿美元的预付款。双方将共同承担开发成本，其中Nurix分担40%，罗氏承担60%。在美国市场的商业化方面，利润与亏损将由两家公司均摊。\n此项合作预计将于2026年第三季度完成，具体取决于相关条件的满足。针对复发或难治性慢性淋巴细胞白血病，Bexobrutideg的三期临床试验计划于2026年夏季启动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155111507","title":"Nurix Therapeutics宣布Bexobrutideg将在2026年欧洲血液学协会大会进行口头报告","url":"https://stock-news.laohu8.com/highlight/detail?id=1155111507","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1155111507?lang=zh_cn&edition=full","pubTime":"2026-05-13 04:06","pubTimestamp":1778616379,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics宣布，其候选药物Bexobrutideg将在2026年欧洲血液学协会（EHA）大会上进行口头报告。这一进展标志着该药物在血液学领域的研究获得了重要认可，并将向全球血液学专家展示其最新的临床数据与研究成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516658359","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658359","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658359?lang=zh_cn&edition=full","pubTime":"2025-03-03 23:35","pubTimestamp":1741016156,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日23时35分，Nurix Therapeutics, Inc.股票出现异动，股价急速跳水5.18%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.36%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032335579637bcd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514331683","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514331683","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514331683?lang=zh_cn&edition=full","pubTime":"2025-02-28 01:39","pubTimestamp":1740677995,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日01时39分，Nurix Therapeutics, Inc.股票出现异动，股价大幅下跌5.10%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022801395598953419&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514726011","title":"Nurix Therapeutics, Inc.盘中异动 临近午盘股价大跌5.04%报16.01美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514726011","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514726011?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:38","pubTimestamp":1740501495,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时38分，Nurix Therapeutics, Inc.股票出现异动，股价大幅跳水5.04%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.04%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于发现、开发和商业化口服小分子疗法，旨在调节细胞蛋白水平，作为一种新型治疗癌症和免疫紊乱的方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600381696300d8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510353845","title":"Nurix Therapeutics, Inc.盘中异动 股价大跌5.00%报17.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2510353845","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2510353845?lang=zh_cn&edition=full","pubTime":"2025-02-12 02:07","pubTimestamp":1739297270,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日02时07分，Nurix Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.46%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212020751961f6c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509231285","title":"Nurix Therapeutics, Inc.盘中异动 大幅上涨5.00%报19.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509231285","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2509231285?lang=zh_cn&edition=full","pubTime":"2025-02-06 01:24","pubTimestamp":1738776295,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日01时24分，Nurix Therapeutics, Inc.股票出现异动，股价急速拉升5.00%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为2.06%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206012455a23aa149&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508178878","title":"Nurix Therapeutics, Inc.盘中异动 临近收盘急速跳水5.07%报18.71美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508178878","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2508178878?lang=zh_cn&edition=full","pubTime":"2025-02-04 04:44","pubTimestamp":1738615480,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日04时44分，Nurix Therapeutics, Inc.股票出现波动，股价大幅跳水5.07%。Nurix Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Nurix Therapeutics, Inc.公司简介：Nurix Therapeutics Inc是一家生物制药公司，专注于口服，小分子疗法的发现，开发和商业化，这些疗法旨在调节细胞蛋白水平，作为癌症和免疫疾病的新型治疗方法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204044440abc15275&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NRIX","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507692295","title":"Nurix Therapeutics, Inc.2024财年实现净利润-1.94亿美元，同比减少34.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507692295","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2507692295?lang=zh_cn&edition=full","pubTime":"2025-01-30 12:01","pubTimestamp":1738209666,"startTime":"0","endTime":"0","summary":"1月30日，Nurix Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-1.94亿美元，同比减少34.72%；其中营业收入为54.55百万美元，同比减少29.15%，每股基本收益为-2.88美元。机构评级：截至2025年1月30日，当前有17家机构对Nurix Therapeutics, Inc.目标价做出预测，其中目标均价为33.18美元，其中最低目标价为26.00美元，最高目标价为41.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130120118a233ed05&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","NRIX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.4528},{"period":"1month","weight":-0.3434},{"period":"3month","weight":-0.4187},{"period":"6month","weight":-0.1017},{"period":"1year","weight":0.1915},{"period":"ytd","weight":-0.2177}],"compareEarnings":[{"period":"1week","weight":-0.0473},{"period":"1month","weight":-0.0592},{"period":"3month","weight":-0.0521},{"period":"6month","weight":-0.0063},{"period":"1year","weight":0.0818},{"period":"ytd","weight":0.0749}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nurix Therapeutics, Inc.于2009年8月27日在特拉华州注册成立，总部位于加利福尼亚州布里斯班。它是一家临床阶段的生物制药公司，专注于靶向蛋白质降解药物的发现、开发和商业化，旨在改善癌症和炎症性疾病患者的治疗选择。在人工智能（AI）集成发现引擎和E3连接酶生物学深厚专业知识的支持下，该公司推进了将蛋白质降解科学转化为临床疗法的差异化方法。Nurix的全资管道包括针对布鲁顿酪氨酸激酶（BTK）和Casitas B系淋巴瘤原癌基因B（CBL-B）的研究候选药物，以及临床前开发中的额外降解剂和降解剂抗体偶联物。Nurix与包括吉利德科学、赛诺菲和辉瑞在内的全球制药合作伙伴合作，还根据共同开发和共同商业化安排，为多个候选药物开展发现计划。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.5,"avgChangeRate":0.009892},{"month":6,"riseRate":0.666667,"avgChangeRate":0.159386},{"month":7,"riseRate":0.5,"avgChangeRate":0.064005},{"month":8,"riseRate":0.571429,"avgChangeRate":0.029558},{"month":9,"riseRate":0.142857,"avgChangeRate":-0.003382},{"month":10,"riseRate":0.571429,"avgChangeRate":0.021965},{"month":11,"riseRate":0.428571,"avgChangeRate":0.064625},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nurix Therapeutics(NRIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}